Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers analyzed 10,225 patient samples from 32 different cancers to better understand TP53 mutations. They found that TP53 mutations were more frequent in patients with poorer survival rates but also identified a way to predict prognosis based on four upregulated genes.
Researchers at Tokyo University of Agriculture and Technology have developed a novel experimental model for dog bladder cancer using 3D organoid culture from urine samples. The model allows for quick determination of chemotherapy and identification of new biomarkers for both human and canine bladder cancer.
Researchers at UVA have identified Hullk, a non-coding RNA that regulates biological processes in cells. The discovery offers potential for targeting and stopping prostate cancer progression with fewer side effects.
A breakthrough new drug CBL0137 has proven effective in mice treated with chemotherapy and is being tested as a potential treatment for all types of cancer, including solid tumours. The drug works by reactivating the body's P53 pathway to kill off damaged cells.
Australian researchers have identified a gene called JMJD6 that plays a key role in the most aggressive form of neuroblastoma. The discovery opens up new possibilities for targeted drug therapy, with promising results shown in animal models.
The freely available data set includes unique comparisons of almost 1,000 cancer cell lines' responses to 453 licensed and experimental drugs. The dataset offers a rich resource for cancer scientists to discover more about how cancer cells work and generate new therapeutics and drug combinations.
A study published in JAMA Oncology reports higher than expected five-year survival rates for patients with melanoma, renal cell carcinoma, and non-small-cell lung cancer treated with nivolumab. The treatment showed durable responses and improved outcomes for patients without cancer-related symptoms.
A new, non-invasive bladder cancer treatment method uses a 'liquid biopsy' from urine to identify molecular underpinnings of each patient's unique bladder cancer. The technique, called conditional reprogramming or CR, has shown promising results in detecting and treating the disease.
A combination of two FDA-approved drugs significantly extended the lives of mice injected with human ovarian cancer cells, altering the natural ratio of macrophages and improving survival. The treatment targets M1 macrophages, which can protect against tumor growth and progression.
A new study published in Science Advances reveals that a cellular switch called CREB plays a key role in directing tumor growth in non-small-cell lung cancer. Researchers found that blocking this switch could have therapeutic benefits for patients with this deadly type of cancer.
Researchers at UT Southwestern Medical Center discovered a new molecular mechanism that indicates PARP inhibitors could be effective in treating all cancers where the drugs are used, including ovarian and prostate cancers. A potential biomarker has been identified, which may indicate when patients can benefit from these drugs.
The FDA has approved erdafitinib as a targeted therapy for patients with advanced bladder cancer who have specific gene mutations in the FGFR3 gene. The drug achieved a 40% overall response rate and was well-tolerated, offering an alternative to existing treatments.
A study by University of Notre Dame researcher Siyuan Zhang and collaborators identified a gene that makes triple-negative breast cancer (TNBC) cells vulnerable to existing therapies. The discovery suggests that a targeted drug therapy may be effective for this aggressive type of breast cancer.
Researchers at Vanderbilt University Medical Center investigated a cancer patient's fatal encephalitis after immunotherapy treatment, revealing a rare viral infection trigger. The study found that a specific T cell population may play a major role in immune-related adverse events and anti-tumor responses.
A new study using a cryo-electron microscope provides critical information for developing anti-nausea drugs that are effective against cancer patients' vomiting side effects. The high-resolution images reveal the attachment site of widely-used setron drugs on serotonin receptors, offering insights into how their design might be improved.
A gene test can identify prostate cancer patients who are likely to respond to a new type of treatment that uses radioactive particles to kill cancer cells. The test detects genetic weaknesses in DNA repair genes, which is linked to high levels of PSMA on the surface of cancer cells.
A new mathematical model describes how highly concentrated antibody solutions separate into different phases, similar to an oil and water mixture. This separation can reduce the stability and shelf-life of some drugs that use monoclonal antibodies.
A Northwestern University study found that many deadliest cancers, such as colon, lung, and liver cancer, receive significantly less nonprofit research funding than breast cancer, leukemia, and other well-funded types. This underfunding could impact research, drug development, and FDA approvals for these life-altering diseases.
Researchers at the University of Minnesota Medical School have identified a cellular mechanism that contributes to drug resistance in colon cancer. The study found that KRAS proteins can transfer between cancer cells via long, thin extensions called tunneling nanotubes, leading to more aggressive and invasive cancer behavior.
Researchers have discovered the precise mechanism behind 5-Fluorouracil resistance in cancer, revealing a previously unknown protein called BOK as the key to understanding this phenomenon. Without BOK, cancer cells become dormant and can survive chemotherapy treatment before mutating into more aggressive forms.
A new study reveals a significantly higher prevalence of anal cancer precursors in women living with HIV compared to previous reports. The researchers recommend developing cost-effective detection and management strategies for this population.
The University of Colorado Cancer Center is enrolling patients in a Phase II clinical trial evaluating the effectiveness of Rucaparib, a PARP inhibitor, as maintenance therapy for endometrial cancer. The trial aims to determine the drug's ability to prevent cancer cell growth and death in patients with metastatic or recurrent disease.
Researchers found adding pembrolizumab to definitive treatment increased overall average PFS by 19.1 months, compared to 6.6 months in historical averages. The study showed the treatment did not lead to new safety issues or decreased patient quality of life.
A new study found that combining targeted drugs palbociclib and crizotinib is significantly more effective against cancer cells in the laboratory than either drug used alone. The combination approach may broaden the clinical use of palbociclib beyond breast cancer to include other tumour types.
A new study from the University of Pittsburgh found a correlation between pre-pregnancy body-mass index (BMI) in mothers and subsequent cancer diagnosis in their offspring. Children born to severely obese mothers had a 57% higher risk of developing leukemia before age 5.
A study published in Journal of Drugs in Dermatology highlights the need for tailored skin cancer prevention programs to reach non-white and younger populations. The research found significant gaps in sun protective knowledge and behavior among these groups, emphasizing the importance of comprehensive community-based solutions.
Researchers propose a 'first-strike' and 'second-strike' strategy to tackle metastatic cancer. The approach aims to eliminate the entire cancer population by sequencing drugs, rather than relying on maximum tolerated dose therapy. This could lead to better outcomes for patients with widespread disease.
Scientists at the University of Toledo have discovered a new class of cancer-killing agents that target and destroy cancer stem cells. These findings hold promise for developing effective treatments for sarcomas and a subtype of breast cancer known as claudin-low breast cancer.
Researchers at Purdue University have discovered a novel set of MYC promoter G-quadruplex stabilizers that demonstrate anticancer activity in human cancer cell cultures. The agents downregulate the expression of the MYC oncogene, which is overexpressed in cancer and associated with all aspects of cancer development.
A new study from the University of Cambridge found that patients with diabetes who have an empathetic GP are at a lower risk of early death. The study analyzed data from 867 individuals and found that those with better experiences of empathy had a significantly lower risk of death over the subsequent 10 years.
Researchers at Moffitt Cancer Center have identified a new drug combination that is effective against metastatic uveal melanoma cells. The combination of an MEK inhibitor and a histone deacetylase (HDAC) inhibitor, such as panobinostat, has been shown to prevent resistance to the MEK inhibitor and enhance its anti-tumor properties.
Researchers found that immune cells were six times more active in tumours resistant to cetuximab. Immunotherapies designed to boost the immune system could be effective against these cancers. A phase II clinical trial has begun to test this approach.
Researchers have identified how precision cancer drugs work, enabling new applications and combination therapies. The discovery reveals the role of PARP proteins in DNA repair, increasing sensitivity to radiation therapy and potential for treating aggressive cancers.
Researchers discovered that bats have higher levels of ABCB1 protein, which reduces DNA damage and cancer incidence. Blocking ABCB1 in bat cells triggers toxic chemical accumulation, leading to cell death. This finding could lead to future therapies for humans to prevent or treat cancer.
A study of 298,434 patients found that married women had a better prognosis after breast cancer diagnosis compared to single or divorced patients. Single patients showed improved outcomes only among white patients and those aged over 35 with hormone receptor-positive tumors.
Researchers at Tokyo University of Science discover that the anticonvulsant drug papaverine blocks the binding of high-mobility group box 1 (HMGB1) to its receptor, reducing inflammation in sepsis and cancer. The study uses a novel computer-based docking approach to find alternative uses for existing drugs.
Researchers developed a computer model that simulates the metabolism of cancer cells, identifying effective drug combinations and predicting tumor growth inhibition. The model has been tested for colorectal cancer and shows promise for other types of cancer, potentially reducing development time and cost.
Researchers found that Medicare beneficiaries with high annual drug spending may pay more out-of-pocket for generics than brands if they use expensive specialty drugs. The study's lead author argues that policy changes are needed to address the issue and ensure generic drug users aren't overpaying.
Research suggests that PI3K inhibitors, a new class of cancer drugs, may cause an increase in pre-cancerous lesions in the pancreas of mice fed high-fat diets. The findings urge doctors to consider a patient's weight before prescribing these drugs, especially for those with pancreatic cancer who are obese.
Researchers have shown that high doses of cyclophosphamide stimulate an immune system attack on lymphoma cells, resolving long-standing questions about the drug's mode of action. The discovery suggests a novel way to spark an immune system strike on certain cancers, particularly those with aggressive characteristics.
Researchers at the University of Akron have developed 3D tumor models that more accurately replicate human tumors than traditional 2D cultures. These models are being used to test new drugs and understand the drivers of triple-negative breast cancer, a type of cancer with limited treatment options.
Researchers found that cancer cells respond differently to targeted drugs based on tumour type and genetic weaknesses. The study suggests rethinking precision medicine and designing clinical trials with both gene faults and tumour type in mind.
A new clinical trial has successfully treated women with HER2-positive breast cancer who have no other treatment options by combining Herceptin with chemotherapy. The two-in-one treatment extended life for patients with high and low levels of the HER2 protein, offering a promising solution to drug resistance.
A study published in JAMA Oncology found that introducing a default physician order into electronic health records reduced daily imaging for cancer patients with advanced cancer by half. This change also saved an average of two minutes per session, resulting in faster treatment courses.
Scientists have identified a novel pathway allowing subcutaneously administered antibodies to bypass the immune system's traditional route. This breakthrough discovery enables targeted delivery of antibodies to the draining lymph node, potentially revolutionizing treatments for inflammatory diseases and cancers.
Researchers developed an algorithm to identify pediatric oncology patients in EHR data, narrowing down patient cohorts for clinical studies. The tool improved accuracy and efficiency in patient selection, paving the way for more effective research on childhood cancers.
Researchers sequenced canine cancer cell lines to identify human-like genetic changes driving canine cancers. The study found 61 genetic variants that match known drivers of human cancer, and showed sensitivity to human medicines.
Researchers found that children with chromosomal defects were almost 12 times more likely to develop cancer than those without birth defects. Children with non-chromosomal defects had a 2.5 times increased risk of cancer compared to those without birth defects.
A University of Colorado Cancer Center study reveals that combining immunotherapy with histone deacetylase (HDAC) inhibition sensitizes cancers to anti-PD1 therapy. HDAC inhibitors upregulate major histocompatibility complex (MHC) proteins, presenting antigens to T cells and making them effective against cancer cells.
Jason S. Lewis, PhD, has received the 2019 Paul C. Aebersold Award from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) for his outstanding contributions to basic nuclear medicine science. His research focuses on developing radiopharmaceuticals for targeted diagnosis and treatment of cancer.
A plant-based diet followed by a man with Crohn's disease led to complete mucosal healing and remission after removing animal products from his diet. The study supports the idea that high-fiber, plant-based diets may benefit patients with Crohn's disease.
Researchers discovered that DBC1 protein helps regulate normal anti-cancer functions and that restoring its expression can prevent cancer development and increase therapy effectiveness. The study found that maintaining DBC1 levels in cancer cells exposed to certain drugs triggers a substantially increased response to treatment.
A human-on-a-chip model developed by Hesperos, Inc. realistically replicates the responses of cancer treatments, enabling more accurate and efficient preclinical testing. The model demonstrated efficacy and toxicity of anticancer drugs on various cell lines, informing treatment decisions for individual patients.
Researchers at the University of Copenhagen have developed a new method to map the properties of water in breast cancer cells, which can help understand how chemotherapy drugs work and potentially lead to new treatments. This approach may also be useful for diagnosing other diseases.
Researchers found that administering anti-inflammatory treatments before surgery can eliminate the spread of cancer cells and promote prolonged survival in animal models. These findings suggest a potential paradigm shift in cancer treatment approaches, particularly for patients undergoing resectable cancers.
Researchers found that FOLFIRINOX prolonged patients' lives by an average of 22.2 months, increasing the chances of complete tumor removal through surgery. More than two-thirds of cancers responded well to treatment, allowing for surgical removal.
The Pew Scholars Program in the Biomedical Sciences supports young researchers investigating connections between embryos and their mothers, tick-borne diseases, and sensory information processing. The program aims to drive significant scientific discoveries by investing in promising scientists at the beginning stages of their careers.
CNIO researchers identified new drug combinations that prevent therapy resistance in mice with glioblastoma by targeting the RAS pathway and telomere maintenance. The study found effective synergistic effects and increased life expectancy in mice by up to 80%.
Researchers from the University of Notre Dame have developed small drug-targeting molecules that can deliver potent drugs to desired sites of disease, including cancer. The molecules use a 'homing' cue to attract drug molecules to sites bearing a tumor, reducing toxic side effects.
Scientists have created a hydrogel that attracts chemotherapy drugs to tumors in mice, reducing side effects caused by the drugs acting on healthy cells. The approach uses cucurbituril to target therapies to a tumor, resulting in improved treatment outcomes and reduced toxicity.